These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20929391)

  • 21. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients.
    Masiá M; Bernal E; Padilla S; Graells ML; Jarrín I; Almenar MV; Molina J; Hernández I; Gutiérrez F
    Atherosclerosis; 2007 Nov; 195(1):167-71. PubMed ID: 17049532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of inflammatory cytokines and endothelial adhesion molecules with immunological, virological, and cardiometabolic disease in HIV-infected individuals.
    Lacerda HR; Falcão Mda C; de Albuquerque VM; Zírpoli JC; Miranda-Filho Dde B; de Albuquerque Mde F; Montarroyos U; Ximenes RA
    J Interferon Cytokine Res; 2014 May; 34(5):385-93. PubMed ID: 24359573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.
    Biron A; Bobin-Dubigeon C; Volteau C; Piroth L; Perré P; Leport C; Prazuck T; Jovelin T; Billard M; Sébille V; Bard JM; Raffi F; Biron C
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1672-8. PubMed ID: 22731114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevalence of cardiovascular risk factors in HIV-infected patients].
    Jericó C; Knobel H; Sorli ML; Montero M; Guelar A; Pedro-Botet J
    Rev Clin Esp; 2006 Dec; 206(11):556-9. PubMed ID: 17178075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.
    Mondy K; Overton ET; Grubb J; Tong S; Seyfried W; Powderly W; Yarasheski K
    Clin Infect Dis; 2007 Mar; 44(5):726-34. PubMed ID: 17278068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011].
    Masiá M; Pérez-Cachafeiro S; Leyes M; López-Aldeguer J; López M; Segura F; Blanco JR; Peña A; Rodríguez F; Vera M; Del Amo J; Gutiérrez F;
    Enferm Infecc Microbiol Clin; 2012 Nov; 30(9):517-27. PubMed ID: 22551653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
    Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients.
    Moreno T; Pérez I; Isasti G; Cabrera F; Santos J; Palacios R
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1195-8. PubMed ID: 23638650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia.
    Tesfaye DY; Kinde S; Medhin G; Megerssa YC; Tadewos A; Tadesse E; Shimelis T
    Diabetes Metab Syndr; 2014; 8(2):102-7. PubMed ID: 24907175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Independent predictors of metabolic syndrome in HIV-infected patients.
    Alencastro PR; Fuchs SC; Wolff FH; Ikeda ML; Brandão AB; Barcellos NT
    AIDS Patient Care STDS; 2011 Nov; 25(11):627-34. PubMed ID: 21936688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.